Laparoscopic cholecystectomy (gallbladder removal) is one of the most common abdominal operations performed worldwide. Despite its minimally invasive approach, up to half of patients experience notable postoperative pain, which often requires opioid painkillers. Reducing perioperative opioid consumption through non-opioid medications helps minimize opioid-related side effects, improve comfort, and enhance postoperative recovery.
The primary purpose of this clinical trial is to compare the pain-relieving and opioid-sparing effects of three intravenous medications (labetalol, magnesium sulfate, and lidocaine) administered during elective laparoscopic cholecystectomy under general anesthesia.
Adult participants aged 18 to 60 years will be randomly assigned to one of three parallel groups:
* Group Lb: Receives intravenous labetalol as an initial loading infusion before induction followed by a continuous infusion during surgery.
* Group M: Receives intravenous magnesium sulfate as an initial loading infusion before induction followed by a continuous infusion during surgery.
* Group L: Receives intravenous lidocaine as an initial loading infusion before induction followed by a continuous infusion during surgery.
The main outcome measured is total perioperative opioid consumption during surgery and throughout the first 24 postoperative hours. Investigators will also assess hemodynamic parameters (heart rate and blood pressure), blood oxygen levels, postoperative pain intensity scores, surgeon satisfaction, and the occurrence of any adverse effects.

Start Date01 Nov 2026

Sponsor / Collaborator

Assiut University

PACTR202607596296076

/ SuspendedNot ApplicableIIT

Intravenous Labetalol versus Hydralazine for controlling severe hypertension in women with Preeclampsia with severe features at NAUTH, Nnewi, Nigeria: A double blind randomized controlled study

Start Date21 Jun 2026

Sponsor / Collaborator-

CTR20260299

/ CompletedNot Applicable

盐酸拉贝洛尔片的生物等效性试验

[Translation] Bioequivalence study of labetalol hydrochloride tablets

主要试验目的：以健康志愿者为试验参与者，在空腹和餐后状态下，以Aspen Pharma Schweiz GmbH, Baar.持有的盐酸拉贝洛尔片（规格：200 mg；商品名：Trandate®）为参比制剂，研究河北仁合益康药业有限公司生产的盐酸拉贝洛尔片（规格：200 mg；受试制剂）的药代动力学，评价受试制剂与参比制剂是否具有生物等效性。次要试验目的：观察受试制剂和参比制剂在健康试验参与者中的安全性。

[Translation]

Primary objective: To investigate the pharmacokinetics of labetalol hydrochloride tablets (200 mg; test formulation) manufactured by Hebei Renhe Yikang Pharmaceutical Co., Ltd., using healthy volunteers in both fasting and postprandial states, with Aspen Pharma Schweiz GmbH, Baar. as the reference formulation, and to evaluate the bioequivalence between the test and reference formulations. Secondary objective: To observe the safety of the test and reference formulations in healthy participants.

Start Date26 Mar 2026

Sponsor / Collaborator

Hebei Renhe Yikang Pharmaceutical Co Ltd.

100 Clinical Results associated with Labetalol Hydrochloride

100 Translational Medicine associated with Labetalol Hydrochloride

100 Patents (Medical) associated with Labetalol Hydrochloride

3,263

Literatures (Medical) associated with Labetalol Hydrochloride

01 Feb 2027·TISSUE & CELL

Chronic labetalol exposure induced dose-dependent testicular toxicity via disruptingt HPG-axis, spermatogenesis and steroidogenic pathways: A biochemical, molecular and histopathological evidence

Article

Author: Alsharif, Khalaf F ; Alzahrani, Khalid J ; Alzahrani, Fuad M ; Jamil, Salim ; Hassan, Hesham M ; Naseem, Muhammad Tahir ; Azmat, Muhammad Bilal

Labetalol (LBL) is a combined-alpha and non-selective β-adrenergic receptor antagonist commonly prescribed for high blood pressure patients. However, LBL intoxication showed severe toxicity including testicular impairments. This experimental study aimed to elucidate the dose-responsive reproductive perturbations of LBL in albino rats. Rats (n = 32) were categorized into control, LBL (200 mg/kg), LBL (250 mg/kg), and LBL (300 mg/kg) group. The cumulative data substantiated that LBL administration suppressed LHCGR, FSHR, AR, ESR1, ESR2, DAZL, STRA8, SYCP3, KIT, CREM, StAR, 3β-HSD, and 17β-HSD. Similarly, LBL exposure promoted pronounced accumulation of ROS & MDA while reducing GSR, CAT, SOD, HO-1, GST & GPx. Furthermore, LBL intoxication adversely diminished the concentrations of testosterone, LH, and FSH against all the tested doses. Testicular inflammation and apoptosis were confirmed by elevated IL-6, NF-κB, COX-2, Bax, IL-1β, Caspase-9, TNF-α, coupled with profoundly impaired Bcl-2 following LBL administration. Histo-morphological examination showed that LBL exposure produced profound architectural distortion of the testicular parenchyma, characterized by extensive seminiferous epithelial deterioration accompanied by marked depletion of spermatogenic cells, high mortality & low sperm viability. Furthermore, LBL administration altered semen parameters including abnormal head, tail, and mid-piece region of sperms thereby suggesting direct testicular toxicity. Collectively, these observations underscore the pronounced testiculotoxic capacity of LBL, highlighting the interplay of oxidative injury, inflammatory mediators, apoptotic processes, and severe histomorphological disruption as principal determinants of its pathogenic effects.

31 Dec 2026·Journal of Maternal-Fetal & Neonatal Medicine

Transient conductive hearing loss as a notable and rare manifestation of preeclampsia: a case report

Article

Author: Chen, Xiuying ; Jin, Linna ; Zhao, Baihui

OBJECTIVE:

To report a case of transient conductive hearing loss secondary to secretory otitis media (SOM) in a patient with preeclampsia, highlight its unique pathophysiological link, and emphasize the importance of recognizing this potential complication.

CASE PRESENTATION:

Preeclampsia is a severe, pregnancy-specific multisystem disorder characterized by new-onset hypertension and proteinuria after 20 weeks of gestation. While endothelial dysfunction and vasospasm are central to its pathophysiology, its clinical manifestations are diverse. Auditory dysfunction, particularly conductive hearing loss, is infrequently reported. We present a case of a 25-year-old gravida 2, para 0 woman diagnosed with preeclampsia at 33 weeks of gestation. She had persistent proteinuria (24-hour urinary protein 1244.7 mg), unstable hypertension (148-165/95-107mmHg) managed with labetalol (100 mg every 8 h, suboptimal adherence), and gestational diabetes. She had no prior history of ear disease, trauma, or ototoxic medication use.At 35w5d gestation, the patient developed sudden bilateral hearing loss, accompanied by mild chest tightness and an elevated brain natriuretic peptide (BNP) level (346.1 pg/ml). Otolaryngology consultation was performed, and otoendoscopic examination revealed bilateral intratympanic fluid. Pure tone audiometry confirmed bilateral conductive hearing loss with significant air-bone gaps (left 30 dB, right 13 dB). Bone conduction thresholds were within normal limits (left 15 dB, right 16 dB), ruling out sensorineural hearing loss. Acoustic immittance audiometry showed bilateral B-type tympanograms, indicative of middle ear effusion. Alternative causes of conductive hearing loss (e.g. upper respiratory infection-related eustachian tube dysfunction, barotrauma, tympanic membrane pathology, middle ear mass) were excluded through clinical evaluation, negative inflammatory markers (C-reactive protein: <0.5 mg/l, white blood cell count: 12.9 × 10^9), and absence of relevant symptoms. Given her deteriorating condition, an emergent Cesarean section was performed at 36 weeks of gestation, delivering a healthy male infant. Postoperatively, supportive management with combined diuretics (furosemide and spironolactone) led to rapid and complete resolution of her hearing deficits within three days. She was discharged on continued antihypertensive therapy and was well at one-month follow-up.

CONCLUSION:

Transient conductive hearing loss due to SOM is a rare manifestation of preeclampsia, likely driven by hypertension-induced increased vascular permeability and altered fluid dynamics. Severe proteinuria may exacerbate systemic fluid imbalance, contributing to middle ear effusion. Early recognition via audiometric and tympanometric evaluation, exclusion of alternative etiologies, and targeted management (e.g. fluid overload reduction) can ensure prompt recovery and improve maternal outcomes. Early recognition and management can improve maternal outcomes by addressing fluid dysregulation and potentially preventing further complications.

01 Dec 2026·Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health

Hospital readmissions and blood pressure management in the early postpartum period following hypertensive disorders of pregnancy

Article

Author: Barry, Natalie ; Xinyi, Kimberly Lim ; Ormesher, Laura ; Myers, Jenny E ; Moran, Chloé

BACKGROUND:

Hypertensive disorders of pregnancy (HDP) affect 8-10% of pregnancies. They are an important cause of maternal morbidity, with crucial implications for long-term cardiovascular health. Whilst antenatal blood pressure (BP) management is well described and evidence-based, postnatal treatment thresholds are higher, management varies, and supporting evidence is limited.

OBJECTIVES:

To characterise postnatal BP trajectories in women with HDP and assess the prevalence of severe hypertension and emergency hospital presentation.

STUDY DESIGN AND MAIN OUTCOME MEASURES:

A retrospective cohort study used routinely collected NHS data from three maternity sites from women exposed to antihypertensive medication either during pregnancy, or within six weeks postpartum. 15,884 BP readings from 570 women were analysed between May and November 2024. Mixed regression models assessed blood pressure trajectories across the treatment groups.

RESULTS:

Severe postnatal hypertension (≥160/110 mmHg) occurred in 39% of women. 29% required ≥1 readmission to maternity triage. Antihypertensives prescribing at discharge was highly variable, with 28 regimens used; 38% of women were discharged without antihypertensive medication. BP peaked five days postpartum, whereas the median discharge occurred on day three. Amlodipine was associated with lower odds of re-admission compared with no treatment (OR 0.58 [95% CI 0.35-0.94]) and labetalol (0.54 [0.50-0.58]), and with a faster early BP decline (p < 0.001).

CONCLUSION:

Postnatal hypertension following HDP is common and remains a major driver of re-attendance. Differences in BP profiles by discharge medication suggest that antihypertensive choice influences early postnatal outcomes. Prospective studies and trials are needed to inform prescribing practices and to reduce morbidity.

News (Medical) associated with Labetalol Hydrochloride

07 Jul 2026

·www.prnewswire.com

Invictus Pharmacy and Mullan Pharmaceutical Inc. Announce Strategic Partnership to Expand Patient Access to FDA-Approved Ganirelix Acetate Injection Through Invictus Pharmacy

Partnership Leverages Invictus Pharmacy's Direct-to-Patient Nationwide Licensed Platform to Deliver FDA-Approved Ganirelix Acetate Injection Across All 50 States NEW YORK, July 7, 2026 /PRNewswire/ -- Invictus Pharmacy, a vertically integrated, nationwide licensed pharmacy platform managed by Invictus Ventures Inc., and Mullan Pharmaceutical Inc., a U.S.-based pharmaceutical company committed to expanding access to affordable, FDA-approved medications through high-capacity manufacturing partnerships and distribution, today announced a strategic partnership to expand patient access to Ganirelix Acetate Injection, 250 mcg/0.5 mL, for patients undergoing fertility treatment across the United States. Continue Reading Mullan Pharma Under the terms of the partnership, Mullan will supply Ganirelix Acetate Injection to Invictus Pharmacy, which, as a licensed dispensing pharmacy, will fulfill valid patient prescriptions through its nationally licensed digital and mail-order pharmacy infrastructure. Through this collaboration, Invictus Pharmacy will help connect fertility patients with this time-sensitive IVF medication with greater speed, transparency, and affordability. Improving Access for Patients During One of Medicine's Most Time-Sensitive Treatments Ganirelix Acetate Injection is a synthetic decapeptide GnRH antagonist indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) as part of an assisted reproductive technology (ART) protocol, including in vitro fertilization (IVF). The medication is administered as a once-daily subcutaneous injection during the mid-to-late follicular phase of the IVF cycle and plays a pivotal role in synchronizing follicular development, preventing premature ovulation, and optimizing the timing of egg retrieval. For fertility patients, timely, uninterrupted access to Ganirelix Acetate is not merely a matter of convenience — it is clinically essential. Treatment windows are measured in days, and even brief disruptions in medication supply can compromise an entire IVF cycle. This partnership is designed to eliminate those disruptions by ensuring the FDA-approved Ganirelix Acetate Injection is reliably supplied to Invictus Pharmacy, which dispenses it to patients pursuant to valid prescriptions through its nationwide licensed fulfillment platform. Invictus Pharmacy on Patient Access and Affordability "Fertility treatment demands precision. From the clinic, from the physician, and from the pharmacy," said Meyer Davidoff , Founder and Chief Executive Officer of Invictus Pharmacy. "At Invictus, our mission is to remove unnecessary barriers between patients and the medications they are prescribed by combining nationwide licensed pharmacy fulfillment, transparent pricing, and direct collaboration with manufacturers. This partnership reflects the broader purpose of our platform: to create a faster, more affordable, and more reliable prescription access model for patients during moments when timing and trust matter most." Advancing Access to Affordable FDA-Approved Medicines "Mullan's mission is straightforward: expand access to vital and essential medicines for every patient," said Marineh Malek, PharmD, RPh, Chief Pharmaceutical Affairs & Regulatory Compliance Officer, Mullan Pharmaceutical Inc. "Ganirelix Acetate is one of the most time-critical medications in reproductive medicine, and the patients who need it are among the most vulnerable in our healthcare system. Invictus Pharmacy's nationwide licensure, dispensing and fulfillment infrastructure, and commitment to transparent pricing make them an ideal partner to ensure that no patient faces an unnecessary barrier to obtaining this medication." Partnership Highlights The collaboration between Invictus Pharmacy and Mullan Pharmaceutical Inc. delivers tangible benefits to patients, fertility specialists, and the reproductive medicine ecosystem: Nationwide Home Delivery: Invictus Pharmacy holds pharmacy licensure across all 50 U.S. states and territories, enabling home delivery of Ganirelix Acetate Injection to fertility patients regardless of geographic location — eliminating the need for patients to source time-sensitive injectable medications from local specialty pharmacies. Direct-to-Patient Pricing: Consistent with Invictus Pharmacy's model of partnering directly to bypass traditional pharmacy benefit intermediaries, this partnership will enable transparent, competitive pricing for Ganirelix Acetate Injection, reducing out-of-pocket costs for patients at one of the most financially demanding stages of fertility treatment. Seamless Digital Experience: Patients will manage their Ganirelix Acetate prescriptions through Invictus Pharmacy's proprietary e-commerce platform at InvictusPharmacy.com, featuring prescription tracking, price transparency, and digital health program integration. Storage and Fulfillment Expertise: Invictus Pharmacy's advanced platform and pharmacy fulfillment infrastructure are designed to ensure uninterrupted prescription access, with particular attention to the handling requirements of injectable fertility medications. About Ganirelix Acetate Injection Ganirelix Acetate Injection, 250 mcg/0.5 mL, is an FDA-approved, single-dose, sterile, prefilled syringe intended for subcutaneous administration. As a GnRH antagonist, Ganirelix Acetate competitively blocks GnRH receptors on the pituitary gland, inducing rapid and reversible suppression of LH and FSH secretion. It is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation in connection with an ART program. Ganirelix Acetate Injection is a prescription medicine. Pregnancy must be excluded before initiating treatment. Important safety information applies. Patients should consult their reproductive endocrinologist or fertility specialist to determine if Ganirelix Acetate is appropriate for their treatment protocol. Please refer to the full Prescribing Information. About Invictus Pharmacy Founded in 2017, Invictus Pharmacy is a vertically integrated, nationwide pharmacy platform specializing in direct-to-consumer prescription access. Managed by New York–based Invictus Ventures Inc., the company operates a network of retail locations, a nationally licensed mail-order pharmacy, a proprietary e-commerce platform, and a claims adjudication technology system. Invictus Pharmacy has served more than one million patients and holds pharmacy licensure across all 50 U.S. states and territories, with its mail-order facility located in New Jersey. Invictus partners directly with drug manufacturers to deliver transparent, direct-to-consumer pricing on brand and generic medications, bypassing traditional pharmacy benefit intermediaries to lower costs and expand patient access. About Invictus Ventures Inc. Invictus Ventures Inc. is a privately held New York–based healthcare technology and pharmacy management company focused on expanding transparent, affordable prescription access for patients, employers, payers, and drug manufacturers. The company manages Invictus Pharmacy, a vertically integrated, nationwide licensed pharmacy platform with retail, mail-order, digital pharmacy, telehealth, claims adjudication, and direct-to-patient fulfillment capabilities, and is developing the TAB Drug Cost Manager platform, an AI-enabled prescription cost optimization system designed to help employers, self-funded health plans, individuals, and manufacturers identify lower-cost dispensing pathways, The company is headquartered at 150 East 52nd Street, Suite 16003, New York, NY 10022. About Mullan Pharmaceutical Inc. Mullan Pharmaceutical Inc. is a U.S.-based pharmaceutical company focused on expanding access to affordable, FDA-approved medications through high-capacity manufacturing partnerships, product registration, and global distribution. Founded in 2022 as a subsidiary of Pasaca Capital, Mullan brings deep expertise in distribution, operations, and a strong capital base to its mission of ensuring that patients and healthcare providers can reliably access high-quality medications at affordable costs. Mullan's product portfolio includes Ganirelix Acetate Injection, Labetalol Hydrochloride Injection, Argatroban Injection, Sevoflurane, and a range of oral solid dosage forms including Metformin, Gabapentin, Bupropion XL, and Celecoxib. The company is headquartered at 800 E Colorado Blvd., Suite 888, Pasadena, CA. For more information, visit . Forward-Looking Statements: This press release contains forward-looking statements. Actual results may differ materially from those anticipated. SOURCE Invictus Pharmacy 21% more press release views with Request a Demo

License out/in

29 Aug 2025

·www.einpresswire.com

April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Adcetris (brentuximab vedotin) Guillain-Barre syndrome FDA determined that no action is necessary at the time based on available information. Arzerra (ofatumumab) Gazyva (obinutuzumab) Riabni (rituximab-arrx) Rituxan (rituximab) Rituxan Hycela (rituximab and hyaluronidase human) Ruxience (rituximab-pvvr) Truxima (rituximab-abbs) Colitis FDA determined that no action is necessary at the time based on available information. Balversa (erdafitinib) Calciphylaxis The "Warnings and Precautions", "Patient Counseling Information", and the "Patient Information" sections of the labeling were updated in April 2022 to include information about soft tissue mineralization, including calciphylaxis. Balversa labeling Bavencio (avelumab) Keytruda (pembrolizumab) Opdivo (nivolumab) Yervoy (ipilimumab) Imfinzi (durvalumab) * Necrotizing fasciitis FDA determined that no action is necessary at this time based on available information. *An administrative error resulted in the omission of Imfinzi (durvalumab) from the list of product names. Imfinzi was added after the initial quarterly report was posted. Beta-blockers Betapace (sotalol hydrochloride) Brevibloc (esmolol hydrochloride) Bystolic (nebivolol) Byvalson (nebivolol and valsartan) Coreg (carvedilol) Coreg CR (carvedilol) Corgard (nadolol) Corzide (nadolol and bendroflumethiazide) Dutoprol (metoprolol succinate and hydrochlorothiazide) Kapspargo Sprinkle (metoprolol succinate) Lopressor HCT (metoprolol tartrate and hydrochlorothiazide) Sectral (acebutolol hydrochloride) Sotylize (sotalol hydrochloride) Tenoretic (atenolol and chlorthalidone) Toprol XL (metoprolol succinate) Trandate (labetalol hydrochloride) Ziac (bisoprolol fumarate and hydrochlorothiazide) Generic products containing beta-blockers Hemangeol (Propranolol Hydrochloride)* Inderal LA (Propranolol Hydrochloride)* Innopran XL (Propranolol hydrochloride)* Lopressor (metoprolol tartrate)* Tenormin (Atenolol)* Hypoglycemia in pediatric patients The "Warnings and Precautions" and "Patient Counseling Information" sections of the labeling were updated between March 2023 and June 2024 to add additional information regarding hypoglycemia. Example: Coreg labeling An administrative error resulted in the inclusion of Betapace AF, Levatol, and Zebeta in the list of product names at the time of the initial quarterly posting. *An administrative error resulted in the omission of Hemangeol, Inderal LA, Innopran XL, Lopressor, and Tenormin from the list of product names and was added after the initial quarterly report was posted. Bosulif (bosutinib monohydrate) Gleevec (imatinib mesylate) Iclusig (ponatinib) Sprycel (dasatinib) Tasigna (nilotinib) Osteonecrosis The "Adverse Reactions" section of the Tasigna labeling was updated in February 2024 to include information about osteonecrosis. Tasigna labeling FDA determined that Gleevec and Sprycel are adequately labeled for osteonecrosis, and that no further regulatory action is needed at this time. FDA determined no action is necessary at this time for Iclusig and Bosulif based on available information. Cablivi (caplacizumab-yhdp) Hemorrhage The "Warnings and Precautions", "Drug Interactions", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about life-threatening and fatal bleeding. Cablivi labeling Cyramza (ramucirumab) Cardiac failure The "Adverse Reactions" section of the labeling was updated in March 2022 to include information about heart failure. Cyramza labeling Doxil (doxorubicin hydrochloride) Acute interstitial pneumonitis FDA determined that no action is necessary at the time based on available information. Gleevec (imatinib mesylate) Tasigna (nilotinib) Myasthenia gravis FDA determined that no action is necessary at the time based on available information. Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (ribociclib; letrozole) Verzenio (abemaciclib) Radiation recall phenomenon FDA determined that no action is necessary at the time based on available information. Lokelma (sodium zirconium cyclosilicate) Gastrointestinal disorders FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pancreatitis FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pneumonitis The "Adverse Reactions", "Warnings and Precautions", and "Patient Counseling Information" sections of the labeling were updated in July 2021 to include information about pneumonitis. Padcev labeling Poteligeo (mogamulizumab-kpkc) Cytomegalovirus viraemia The "Adverse Reactions" section of the labeling was updated in March 2022 to include cytomegalovirus infection. Poteligeo labeling Procysbi (cysteamine bitartrate) Generic products containing cysteamine bitartrate Fibrosing colonopathy The "Warnings and Precautions", "Adverse Reactions", "Patient Information", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about fibrosing colonopathy. Example: Procysbi labeling Sarclisa (isatuximab-irfc) Herpes zoster The "Dosage and Administration", "Adverse Reactions", and "Patient Information" sections of the labeling were updated in July 2022 to include information about herpes zoster. Sarclisa labeling Sprycel (dasatinib) Drug-induced liver injury The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information” and “Patient Information” sections of the labeling were updated in February 2023 to include information about hepatotoxicity. Sprycel labeling Taxotere (docetaxel) Rhabdomyolysis FDA determined that no action is necessary at the time based on available information. Veklury (remdesivir) Bradycardia FDA determined that no action is necessary at the time based on available information. Zepzelca (lurbinectedin) Extravasation The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in April 2022 to include information about extravasation. Zepzelca labeling Zepzelca (lurbinectedin) Tumor lysis syndrome The “Adverse Reactions” section of the labeling was updated in April 2022 to include tumor lysis syndrome. Zepzelca labeling Zepzelca (lurbinectedin) Rhabdomyolysis The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information”, and “Patient Information” sections of the labeling were updated in April 2022 to include rhabdomyolysis. Zepzelca labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

03 Sep 2024

·www.pharmaceutical-technology.com

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

At the ESC Congress, Dr. Milton Packer highlighted recent research into beta blocker treatment for myocardial infarction. Credit: luchschenF via Shutterstock. A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at the European Society of Cardiology (ESC) Congress, held from 31 August to 2 September. Over the past 40 years, the research space has operated on an understanding that immediate inhibition by beta-blockers reduces left ventricular rupture, and further myocardial infarction , said Dr. Milton Packer, distinguished scholar in cardiovascular science at Baylor University Medical Center, Dallas. Additionally, the belief was that delayed long-term blockade can lead to left ventricular dysfunction, he said. Beta-blockers are a class of drugs that act by inhibiting the actions of hormones such as adrenaline to slow down the heart. Commonly used beta blockers include Abbott ’s Tenormin (atenolol), MSD’s Cardicor (bisoprolol), and GSK ’s Trandate (labetalol). However, Packer explained that the beta blocker response has changed as percutaneous interventions, reperfusion therapies, antiplatelet drugs and more have entered the treatment landscape for myocardial infarction. At the ongoing ESC Congress talk titled “Should we give beta blockers post-myocardial infarction?” Packer said that questions have been raised surrounding the use of the drugs in patients with myocardial infarction and preserved ejection fraction, referencing the Phase IIII REDUCE-AMI study (NCT03278509). See Also: Novavax wins FDA emergency approval for updated Covid-19 vaccine Combating Pharmaceutical Crime with On-Dose Authentication REDUCE-AMI, which was funded by the Swedish Research Council, tested the use of beta-blockers after myocardial infarction and preserved ejection fraction. The study found that for patients with acute myocardial infarction who underwent early coronary angiography and had preserved left ventricular ejection fraction, long-term beta-blocker treatment did not lower the risk of death from any cause or new myocardial infarctions compared to no beta-blocker use. Despite the conclusion of the REDUCE-AMI study, Packer highlighted the fact that researchers have only investigated and proven the effectiveness of non-selective beta blockers in post-myocardial infarction trials, so further research is required. He added that physicians will have to take into account the degree of beta-blockade in future treatment regimens.

VaccinePhase 3Drug ApprovalClinical Result

100 Deals associated with Labetalol Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00600	Labetalol Hydrochloride	C07AG01	DB00598

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension	United States	Schering Corp.	01 Aug 1984
Hypertension	United States	Alvogen, Inc.	01 Aug 1984
Essential Hypertension	Japan	Sandoz AG	07 Oct 1982

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05139238 (CTgov)	Phase 4	Pre-Eclampsia	2	Nifedipine (Oral Nifedipine)	ribmpyouok = ysdnqdqfka zxlbeyhqjc (xifzwlozwk, lqzrmucjev - ztpwngsnqk) View more	-	06 May 2026
				Labetalol (Intravenous Labetalol)	ribmpyouok = ymvviahtcj zxlbeyhqjc (xifzwlozwk, hppxxeyrdt - klreafqmrb) View more
NCT04343235 (CTgov)	Phase 4	Hypertension, Pregnancy-Induced \| Pre-Eclampsia	13	labetalol+furosemide (Labetalol + Furosemide)	lfhgpwpxwy = jqjihucigc heturjxrgz (jkqrdbnttd, vvsjovrgbk - wgslksqerg) View more	-	23 Oct 2023
				labetalol (Labetalol Only)	lfhgpwpxwy = vyhcmgysmn heturjxrgz (jkqrdbnttd, qdmgdvzadi - zyirwjpgab) View more
NCT04116112 (BEST-II, CTgov)	Phase 2	Thrombosis \| Stroke	120	Labetalol+Nicardipine+Hydralazine (Higher Systolic Blood Pressure (SBP) Target)	aspjvkcxae(mkeypabowv) = rxphmsefqw ybedelkifi (stzmjlggzr, ueoxjlatda - keeiwyyhab) View more	-	12 Oct 2023
				Labetalol+Nicardipine+Hydralazine (Lower SBP (<160 mmHg) Target)	aspjvkcxae(mkeypabowv) = apyywztpov ybedelkifi (stzmjlggzr, uhulskrauf - gafqkgjukr) View more
NCT04539379 (ZU-IRB#: 6353-23-3-2020, Pubmed \| J Clin Monit Comput)	Not Applicable	Pre-Eclampsia	-	Magnesium sulfate	rjbaybkxeu(ikxcnnrzxm) = lmmaphxbec vmdenqfqbs (tlqtmzvcjt )	Positive	01 Aug 2023
				Labetalol	rjbaybkxeu(ikxcnnrzxm) = qifcaeimqn vmdenqfqbs (tlqtmzvcjt )
NCT03506724 (CTgov)	Phase 4	Pre-Eclampsia	109	Labetalol (Intravenous Labetalol)	blorsctthe(eepdrirhby) = xtpsyevcqb gfxzurmyww (usnenfvwjl, mgoomlyvqm - xeuwwusvhi) View more	-	24 May 2021
				Nifedipine (Oral Nifedipine)	blorsctthe(eepdrirhby) = okvpmrpvql gfxzurmyww (usnenfvwjl, fgtbacvkap - moabtpradd) View more
NCT01114971 (CTgov)	Phase 4	Pain, Postoperative	75	Esmolol+Labetalol (Fentanyl)	ammzikmivk(uupsfxudyv) = vfmbqoivfi kpxkopbaax (brbndlxtyp, 2) View more	-	20 Feb 2020
				Fentanyl+Esmolol (Labetalol)	ammzikmivk(uupsfxudyv) = tdvvjvdtlz kpxkopbaax (brbndlxtyp, 3) View more
NCT02168309 (CTgov)	Not Applicable	Hypertension	50	Labetalol (Labetalol)	woikrjjvqf(gljkygocjw) = nsxddhrrlp kubrvhknmk (rdmqbugxjh, 32.5) View more	-	13 Dec 2017
				Nifedipine (Nifedipine)	woikrjjvqf(gljkygocjw) = ewrrbtojxm kubrvhknmk (rdmqbugxjh, 27.6) View more
ISRCTN40973936 (Pubmed \| Hypertension)	Not Applicable	Hypertension, Pregnancy-Induced First line	112	Labetalol	xprlgcuchj(pwuwjkubwk) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis vookrmkmuf (rkmssayvbo )	-	01 Nov 2017
				Nifedipine-modified release
NCT02168309 (Pubmed \| Hypertens Pregnancy)	Not Applicable	Hypertension	50	Oral labetalol	dlwxpbpkec(czjgzkfmjk) = objxeeadgy rtwiukbcqz (htlzpyeywz )	-	02 Jan 2017
				Oral extended release nifedipine	dlwxpbpkec(czjgzkfmjk) = uouoiazszc rtwiukbcqz (htlzpyeywz )
NCT00765648 (CLUE trial \| CLUE, CTgov)	Phase 4	Hypertension	226	Nicardipine (Nicardipine)	flsxrouciu = ipldjxxhpv fxhtdppfsx (lrwrirounv, aguntkxqjo - rnfcyamtqd) View more	-	11 Dec 2014
				Labetalol (Labetalol)	flsxrouciu = dfzfbfqgwu fxhtdppfsx (lrwrirounv, kyrhuvgddg - yhcmadhctm) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis